38 Week Extension Study to CAIN457C2303
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
38 Week Extension Study to CAIN457C2303 is a clinical trial[1].
Key Facts
- 38 Week Extension Study to CAIN457C2303 is located in Hong Kong[2].
- 38 Week Extension Study to CAIN457C2303 is in the country of Egypt[3].
- 38 Week Extension Study to CAIN457C2303 is in the country of France[4].
- 38 Week Extension Study to CAIN457C2303 is in the country of Germany[5].
- 38 Week Extension Study to CAIN457C2303 is in the country of Greece[6].
- 38 Week Extension Study to CAIN457C2303 is in the country of Israel[7].
- 38 Week Extension Study to CAIN457C2303 is in the country of Jordan[8].
- 38 Week Extension Study to CAIN457C2303's instance of is recorded as clinical trial[9].
- 38 Week Extension Study to CAIN457C2303's start time is recorded as +2010-03-31T00:00:00Z[10].
- 38 Week Extension Study to CAIN457C2303's end time is recorded as +2011-01-31T00:00:00Z[11].
- 38 Week Extension Study to CAIN457C2303's sponsor is recorded as Novartis[12].
- 38 Week Extension Study to CAIN457C2303's main subject is recorded as uveitis[13].
- 38 Week Extension Study to CAIN457C2303's number of participants is recorded as {'unit': '1', 'amount': '+59'}[14].
- 38 Week Extension Study to CAIN457C2303's title is recorded as A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study)[15].
- 38 Week Extension Study to CAIN457C2303's short name is recorded as SHIELD[16].
- 38 Week Extension Study to CAIN457C2303's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[17].
- 38 Week Extension Study to CAIN457C2303's ClinicalTrials.gov ID is recorded as NCT01093846[18].
- 38 Week Extension Study to CAIN457C2303's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+100'}[19].
- 38 Week Extension Study to CAIN457C2303's clinical trial phase is recorded as phase III clinical trial[20].
- 38 Week Extension Study to CAIN457C2303's research site is recorded as Novartis[21].
- 38 Week Extension Study to CAIN457C2303's study type is recorded as interventional study[22].